and joint pain.
14 Continued BZD use was predicted by older age, 14 female gender, 15 divorce, 15 psychopathology, 16 poor health, 17 pain, 14 number of GP contacts, 15 insomnia, 15 a history of BZD use, 17 daily BZD use, 18 use of higher potency BZDs, 19 long duration of BZD use, 20 high BZD dosage, 20 and hypnotic use. 20 Living alone was associated with a decreased risk of continued BZD use. 14 However, findings are inconsistent across studies, possibly due to the investigation of only a few determinants per study, 12 distinct definitions of the outcome variable (psychotropic use, 12 BZD use, 18 onset of use, 16 onset of chronic use 14 ) , dissimilar data collection (pharmacy databases, 18 self-report 21 ), differing study samples (all ages, 22 old subjects 5 ) and included determinants. Thus, it remains unclear which of the above mentioned predictors are most important in the prediction of BZD use. Additionally, the associations of course of psychopathology and life events with BZD use have not been studied in longitudinal research yet.
We aimed to identify the (most important) independent risk factors of initiated BZD use and continued BZD use during a 2-year followup period. Therefore, we included the above described previously investigated predictors of BZD use and several not previously investigated determinants (e.g., course of psychopathology and life events) in order to investigate which variables would fall off (and thus be less relevant) and which would remain significant in the a multivariate model.
MAteriALs AND MetHoDs subjects
Subjects participated in the baseline and 2-year assessment of the Netherlands Study of Depression and Anxiety (NESDA), an ongoing 8-year longitudinal cohort study of 2981 respondents aged 18 through 65 years. 23 NESDA was designed to be representative of individuals with depressive and/or anxiety disorders in different health care settings and developmental stages of illness. Therefore, subjects with no symptoms ("controls"), those with earlier episodes or at risk, and those with a depressive or anxiety disorder were recruited from the community, general practices and specialized mental health care institutions throughout the Netherlands. 23 The baseline assessment included a medical exam, an inperson interview, and self-report questionnaires. 23 The study protocol was approved by the Ethical Review Board of each participating center and all subjects signed an informed consent at the baseline assessment. 23 After 2 years, a face-to-face follow-up was conducted. 24 Data from baseline and follow-up were used in this analysis. We excluded subjects with lacking follow-up data (n=385) and those with epilepsy (n=22), as epilepsy can be an indication for long-term BZD use. 25 Missing data were imputed by the mean for 4.2 % of data points. Imputation did not importantly change our results. After exclusion, 2574 subjects remained and comprised the sample of the following analyses.
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To identify the determinants of initiated BZD use, only subjects who did not use BZDs at baseline were included (n=2205). They were divided into subjects who initiated BZD use in the time interval between baseline and follow-up ("initiated use", n=103) and those who did not ("nonuse", n=2102). For the investigation of continued BZD use, only subjects who used BZDs at baseline were included (n=369) and divided into subjects who still reported BZD use at follow-up ("continued use", n=200) and subjects who had discontinued use between baseline and follow-up ("discontinued use", n=169).
MeAsUres

BZD Use
BZD use at baseline/follow-up (including z-drugs; Anatomical Therapeutic 27 The presence of insomnia was determined using the Insomnia Rating Scale. 28 The severity of depressive symptoms was measured by the cognitive/mood scale of the Inventory of Depressive Symptomatology Self Report. 29 Locus of control was assessed by a 5-item mastery scale. 30 Personality traits were assessed with the Neuroticism Extraversion Openness-Five Factor Inventory. 31 Antidepressant use (with ATC codes N06AA, N06AB, N06AF, N06AX or N06AG) was reported during the interview.
Physical characteristics. An inventory of somatic diseases was made by counting the number of chronic illnesses a subject experienced at the baseline assessment. 11 The number of GP consultations in the 6 months before baseline assessment was assessed with the trimbos/ iMTA questionnaire for costs associated with psychiatric illness.
32
Pain complaints were measured with the Chronic Graded Pain Scale. 33 Smoking was reported during the interview. Alcohol dependence was assessed with the corresponding Composite International Diagnostic
Interview section.
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Characteristics of BZD Use at Baseline
As characteristics of use were associated with continued use in previous research, 18, 19 follow-up with symptoms of at least mild severity was calculated using the Life Chart Interview. 35 Three categories were established: 1) no anxiety/depressive symptoms during follow-up, 2) less than half of follow-up anxiety/depressive symptoms, and 3) more than half of followup anxiety/depressive symptoms.
Life events. The incidence of 12 negative life events during followup was assessed with the List of Threatening Events Questionnaire. 36 The List of Threatening Events Questionnaire was extended by 7 items referring to positive life events: (1) "immediate family member recovered from serious illness", (2) "met a new partner", (3) "became friends", (4) "have been on holiday", (5) "new job or important promotion", (6) "education completed", and (7) All analyses were adjusted for gender and age. Analyses were conducted with SPSS 16.0 for Windows. Significance was inferred at P < 0.05.
resULts
BZD Use
The prevalence rates of BZD use at baseline and follow-up were 14.3% 
Predictors of continued BZD Use
In Table 2 , we present the characteristics of subjects who continued BZD use (n=200) as compared with those who discontinued BZD use (n=169)
as investigated in subjects who were using BZDs at baseline (n=369).
In multivariate analyses, older age (OR per year=1. 
DiscUssioN
This longitudinal cohort study aimed to identify the most important predictors of initiated and continued BZD use. In the multivariate model, which included the most consistently identified predictors of BZD use from previous research plus a number of not previously investigated determinants, the following variables appeared to be most important.
Initiated BZD use (in nonusers at baseline) was more likely in subjects with insomnia, who had enduring anxiety symptoms, who entered secondary care, and who had used BZDs in the past. It was less likely in subjects who experienced a higher number of positive life events. Continued BZD use (among baseline BZD users) was more likely in older subjects with more severe anxiety and a long baseline duration of BZD use, but less likely in subjects who left secondary care during follow-up.
Regarding the initiation of BZD use, we confirmed previous research, which found that subjects with a history of BZD use were more likely to re-start BZD use due to withdrawal symptoms or a new episode of psychopathology. 37 Furthermore, it was consistent with earlier studies 21 that anxiety and insomnia predicted initiated BZD use and were probably the main reasons to issue new BZD prescriptions. However, the following 4 insights were new: 1) Mainly, subjects who were anxious most of the 2-year follow-up time initiated BZD use, indicating that a short duration of anxiety does not necessarily lead to BZD use. 2) Positive life events were associated with less initiation of BZD use, possibly by alleviation of emotional distress both directly and by buffering the adverse consequences of negative life events. 38 3) Entry of secondary care increased the likelihood that BZDs were initiated. This might be due to the necessity of adding BZDs to the treatment regime in patients who were referred to secondary care because of unsuccessful primary care treatment. 4) Gender, age, marital status, alcohol abuse, antidepressant use, smoking, physical health, and pain were no independent determinants of initiated BZD use in the current model, although they were in previous research. [12] [13] [14] As we corrected for a broad set of important confounders in our multivariate model, it seems that insomnia, enduring anxiety symptoms, entry into secondary care, and BZD use in the past were more important predictors for the initiation of BZD use than these variables were.
Regarding continuation of BZD use, we confirmed previous research that older age, 14 more severe anxiety, 16 and a longer duration of BZD use in the past 17 were important predictors. Yet, the following 2 findings were new: 1) As compared with primary care patients, subjects who left secondary care during follow-up were more likely to discontinue BZD use, possibly because their mental health status had improved.
However, secondary care treatment remained an independent predictor in our model even after adjustment for severity of psychopathology. 2)
Continued BZD use was not predicted by gender, marital status, health, pain, living status, GP contacts, insomnia, daily BZD use, potency of BZD, duration of use, BZD dosage, and hypnotic use in our multivariate model, although these variables were important determinants in previous research. 14, 15, 17, 20 Again, as we corrected for a broad set of important confounders in our multivariate model, it seems that severe anxiety, a long baseline duration of BZD use and leaving secondary care during follow-up were more important in the explanation of continuation of BZD use than above described variables were.
Our study had several limitations. Because of the medium sized BZD user group and large number of determinants tested, the power of our study was limited and we were not able to investigate subgroups of users.
Furthermore, although participants were asked to bring drug containers to the interview, one fourth of the subjects did not do so. This might have introduced recall bias and some error. Finally, we could not include all previously investigated determinants as some of these were not included in the NESDA study (i.e., stress 12 and life satisfaction 21 ). This paper is limited to subject characteristics and does not include interactions with prescribers who also may influence BZD use. There were also several strengths to our study. We were able to include the most consistently research as well as a number of never investigated longitudinal variables in a comprehensive multivariate model. That enabled us to identify the most important independent determinants of initiated and continued BZD use.
In conclusion, this study revealed that insomnia and anxiety were the main reasons for initiated BZD use, whereas older age and anxiety were the main reason for continued BZD use. Gender, education, pain, and physical health appeared to be less important.
